Logo
x

Search

Subscribe Now

NSCLC

Johnson & Johnson Receives the EC’s Approval for SC Rybrevant to Treat Advanced EGFR-Mutated NSCLC

Johnson & Johnson Receives the EC’s Approval for SC Rybrevant to Treat Advanced EGFR-Mutated NSCLC

  • April 9, 2025
AstraZeneca Reports the EC’s Approval of Imfinzi Regimen as Perioperative Treatment of NSCLC

AstraZeneca Reports the EC’s Approval of Imfinzi Regimen as Perioperative Treatment of NSCLC

  • April 4, 2025
BMS’ Opdivo Receives the CHMP’s Positive Opinion as a Neoadjuvant Treatment of Resectable NSCLC

BMS’ Opdivo Receives the CHMP’s Positive Opinion as a Neoadjuvant Treatment of Resectable NSCLC

  • March 31, 2025
Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

  • March 27, 2025
Servier Collaborates with Black Diamond Therapeutics to Advance BDTX-4933 for Solid Tumors

Servier Collaborates with Black Diamond Therapeutics to Advance BDTX-4933 for Solid Tumors

  • March 20, 2025
Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC)

Innovent and HUTCHMED Report P-II/III (FRUSICA-2) Trial Data of Sintilimab + Fruquintinib for Metastatic Renal Cell Carcinoma (RCC...

  • March 19, 2025
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.